Business Wire

nCipher Security Delivers Trust, Integrity and Control to Business Critical Information and Applications

Share

nCipher Security, the provider of trust, integrity and control for business critical information and applications, officially launched today creating a new leader in the general purpose hardware security module (HSM) marketplace.

Today’s fast moving digital environment offers opportunities to enhance customer satisfaction, improve operational efficiency and gain competitive advantage, but in doing so also raises new security challenges. nCipher’s market-leading solutions and services allow organizations to keep pace with innovation while protecting their business critical assets from security breaches.

The world’s leading organizations have depended on nCipher nShield HSMs for more than 20 years to provide a root of trust for their business critical applications and meet their cybersecurity needs. Our customers include 5 of the top 10 Fortune 100 and 10 of the top 20 FTSE 100 companies.

Organizations are also now subject to an increasing number of strict compliance mandates such as the EU General Data Protection Regulation (GDPR), California Data Breach Notification Law and Australia Privacy Amendment Act 2017. nCipher provides the highest level of assurance in protecting sensitive data, enabling organizations to meet these very stringent compliance controls.

Cindy Provin, Chief Executive Officer, nCipher Security says:
“I am both excited and proud to lead an innovative, agile, world-class team helping our customers as they embrace a digital future. nCipher nShield HSMs are a critical component in securing today’s business critical applications as well as the journey to the cloud, new digital payment methods and the internet of things. With high profile data breaches hitting the headlines daily and newly enforced legislation, organizations need to get security right.”

nCipher customers rely on nShield HSMs to provide a root of trust for a wide variety of business applications including public key infrastructures (PKIs), SSL/TLS encryption key protection, code signing, digital signing and blockchain. As growth in the Internet of Things (IoT) creates greater demand for device IDs and certificates, nShield HSMs will continue to support critical security measures such as device authentication using digital certificates.

nCipher highlights:

  • World class, committed and experienced leadership team
  • Exceptional technology supported by 32 patents
  • 700+ years of applied cryptography and security experience
  • Strong third party certifications – FIPS 140-2, eIDAS, Common Criteria
  • 20-year heritage providing market-leading general purpose HSMs
  • Strong installed customer base including 5 of the top 10 Fortune 100 and 10 of the top 20 FTSE 100
  • Global network of strategic technology partners and distributors

nCipher Security is now a separate stand-alone business within Thales and held separate from the rest of the Thales Group pending its divestiture to a third party buyer. This results from Thales Group’s offer to acquire Gemalto and the demands of a number of antitrust agencies, including the European Commission, to create a strong player in the general purpose HSM space in order to preserve competition in this important market place and continued supply and innovations to our nShield customers. Thales and Gemalto continue to work constructively with the competent antitrust authorities to obtain the remaining merger control regulatory clearances in Russia and the United States. In addition, Thales and Gemalto are seeking regulatory clearance relating to foreign investments from the competent authority in Russia.

nCipher Security will be exhibiting at RSA Conference 2019 on booth #3106, to learn how our cryptographic solutions guard against today’s threats and attacks, enable compliance and protect your business applications.

Follow us on LinkedIn, Twitter, Facebook and Instagram – search nCipherSecurity.

About nCipher Security

Today’s fast moving digital environment enhances customer satisfaction, gives competitive advantage and improves operational efficiency. It also multiplies the security risks.

nCipher Security, a leader in the general purpose hardware security module (HSM) market, empowers world-leading organizations by delivering trust, integrity and control to their business critical information and applications.

Our cryptographic solutions secure emerging technologies – cloud, IoT, blockchain, digital payments – and help meet new compliance mandates, using the same proven technology that global organizations depend on today to protect against threats to their sensitive data, network communications and enterprise infrastructure. We deliver trust for your business critical applications, ensuring the integrity of your data and putting you in complete control – today, tomorrow, at all times. www.ncipher.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information please contact:

nCipher Security
Megan Nemeh megan.nemeh@ncipher.com +1 408 887 5064
Liz Harris liz.harris@ncipher.com +44 7973 973648

US Media
Bospar PR PRfornCipher@bospar.com

UK Media
Hotwire PR nCipher@hotwireglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Caranx Medical announces successful world first robotic assisted transcatheter heart valve implantation in an animal16.4.2024 11:30:00 EEST | Press release

Caranx Medical (‘Caranx’), a French medical device company specializing in the development of autonomous robot to democratize access to Transcatheter Aortic Valve Implantation (TAVI), a lifesaving procedure, today announced the successful world first robotic assisted heart valve (aortic valve) implantation in an animal. The assisted heart valve implantation in the animal was successfully performed by Dr. Stéphane Lopez, Caranx CMO Dr. Eric Sejor, Caranx CTO Pierre Berthet-Rayne and Caranx team. “This groundbreaking achievement is the result of hard teamwork. At Caranx Medical, we are dedicated to improving patients' lives through true innovation. This successful transcatheter robotic aortic valve implantation marks the first step toward a new generation of intelligent robots guided by AI, set to transform healthcare as we know it” says Pierre Berthet-Rayne, PhD, co-founder and CTO of Caranx. “This major medical first lies not only in the technical achievement of Caranx Medical's engine

Arthur D. Little Publishes Human After All – Latest Edition of PRISM Magazine16.4.2024 11:00:00 EEST | Press release

Arthur D. Little (ADL) has published Human After All – the latest edition of its strategy and innovation magazine PRISM. As we enter the era of AI, the first edition of 2024 highlights the importance of taking a human-centric approach to business management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416226137/en/ Arthur D. Little has published Human After All – the latest edition of its strategy and innovation magazine PRISM. (Graphic: Business Wire) The magazine features seven key articles: Optimistic global CEOs focus on people and skills in an AI future - Our lead article shares highlights from the ADL 2024 CEO Insights Study, finding that CEOs are increasingly confident of future economic success. The people-centric lab of the future – how technology and AI can play a key role in driving breakthrough innovation by enabling people to become perfect innovators. The future workforce - Recruiting and retaining vital

Magnesium Capital closes oversubscribed inaugural Fund at €135m hard cap16.4.2024 10:32:00 EEST | Press release

Magnesium Capital, the Energy Transition buyout specialist, is delighted to announce the successful close of its inaugural Fund, Magnesium Capital I, at its hard cap of €135m, exceeding the €100m Fund target. The final close occurred less than a year after the Fund’s first close with Magnesium attracting blue-clip institutional investors from the US, Europe and the UK. Magnesium focuses on profitable European companies with proven technologies or tech-enabled services that are positively impacting the decarbonisation of the production, distribution and consumption of energy. The team has been backing the buyouts of such businesses for a number of years on a direct deal basis. Since inception, Magnesium has completed seven platform investments, signed six follow-on acquisitions and exited two investments for 4.2x gross MOIC. The combined impact of these portfolio companies already directly contributes to the avoidance of over 30 million tonnes of CO2 equivalent per annum. Ian Jones, Man

Money20/20 Europe Unveils 2024 Speaker Lineup Under ‘Human X Machine’ Show Theme16.4.2024 10:00:00 EEST | Press release

Money20/20, the world’s leading fintech show and the place where money does business, unveils its agenda for its upcoming Europe show in Amsterdam, 4-6 June. 350+ speakers are expected to take the stage in Amsterdam this year including C-suite executives from global banks such as Deutsche Bank and ING; fintech players such as Adyen and Revolut, senior representatives from the European Central Bank and the European Commission, and blockchain solution providers such as Ripple. The show promises an amalgamation of expertise, from the Wirecard whistleblower Pav Gill to tech evangelist Prince Constantijn van Oranje-Nassau of the Netherlands. Under the theme of ‘Human X Machine’, Money20/20 Europe 2024 will explore the dynamic relationship between humans and intelligent machines, focusing on how the partnership between artificial and human intelligence will forge a new era in finance. In line with this, Money20/20 Europe also welcomes the CEOs of AI firms including Mistral AI, Datasnipper an

MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH00216.4.2024 10:00:00 EEST | Press release

MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today reports positive topline results from its Phase 2a clinical trial with MH002 in the orphan disease indication Pouchitis. MRM Health’s MH002-PC-201 study was a multi-center, open-label clinical trial in 14 acute Pouchitis (PC) patients at multiple clinical sites in Belgium and Italy. The study was designed to evaluate safety (primary objective), initial efficacy, and mechanistic effects of MH002 over 8 weeks. More information about the trial is available at clinicaltrialsregister.eu. The trial met its primary objective with an excellent safety and tolerability at a fixed dose of 400mg per day over 8 weeks’ administration. Treatment-Emergent Adverse Events (TEAE) reported were predominantly mild and unrelated, and there was no evidence of adverse reactions related to MH002. It also demonstrated initial efficacy in clinically relevant parameters,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye